Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M02D1 in advanced non-small cell lung cancer and solid tumors
NCT05949619Phase 2Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BL-M02D1 in non-small cell lung cancer (NSCLC) and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Recommended Phase II Dose at 21 days and Objective Response Rate at 24 months. Started Sep 2023; status: active, not recruiting.
02
Drugs
BL-M02D1
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05949619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05949619.